New criteria and new methodological tools for devising criteria sets of inflammatory rheumatic diseases.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 01 10 2019
accepted: 09 12 2019
pubmed: 28 2 2020
medline: 18 9 2020
entrez: 28 2 2020
Statut: ppublish

Résumé

Rheumatologists use classification criteria to separate patients with inflammatory rheumatic diseases (IRD). They change over time, and the concepts of the diseases also change. The paradigm is currently moving as the goal of classification in the future will be more to select which patients may be relevant for a specific treatment rather than to describe their characteristics. Therefore, the challenge will be to reclassify multifactorial diseases on the basis of their biological mechanisms rather than their clinical phenotype. Currently, various projects are trying to reclassify diseases using bioinformatics approaches and in the near future the use of advanced machine learning algorithms with large omics datasets could lead to new classification models not only based on a clinical phenotype but also on complex biological profile and common sensitivity to targeted treatment. These models would highlight common biological pathways between patients classified in the same cluster and provide a deep understanding of the mechanisms involved in the patient's clinical phenotype. Such approaches would ultimately lead to classification models that rely more on biological causes than on symptoms. This overview on current classification of subgroups of IRD summarises the classification criteria that we use routinely, and how we will classify IRD in the future using bioinformatics and artificial intelligence techniques.

Identifiants

pubmed: 32105592
pii: 14833

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

776-782

Auteurs

Nathan Foulquier (N)

UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest; and LATIM, Laboratoire de Traitement de l'Information Médicale, UMR 1101, IBRBS, Université de Brest, Inserm, CHU, Brest, France.

Pascal Redou (P)

LATIM, Laboratoire de Traitement de l'Information Médicale, UMR 1101, IBRBS, Université de Brest, Inserm, CHU, Brest, France.

Jacques Olivier Pers (JO)

UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest, France.

Alain Saraux (A)

UMR1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, CHU Brest, LabEx IGO, Brest; and Rheumatology Unit, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU, Brest, France. alain.saraux@chu-brest.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH